Patients with advanced cardiometabolic disease face a higher risk for major adverse cardiac events after metabolic bariatric surgery.

Researchers evaluated the impact of menopausal hormone therapy on cardiovascular disease risk among women in midlife experiencing vasomotor symptoms.

Heart failure is linked to worse global cognitive performance, with patients who have reduced ejection fraction facing the highest impairment risk.

GLP-1 receptor agonists are linked to lower rates of all-cause mortality and ischemic stroke in adults with obesity and elevated C-reactive protein.

Transgender and gender diverse veterans face a higher risk for incident heart failure than cisgender women, but a lower risk than cisgender men.

A new generic hormone therapy patch used to treat symptoms of menopause will be available following recent FDA approval.

Patients with heavily calcified coronary lesions treated with a 2-Hz intravascular lithotripsy catheter have low MACE rates at 1 year.

Spatial frequency domain imaging offers noninvasive measures of skin involvement, aligning with established assessments for systemic sclerosis.

GLP-1 receptor agonist use in patients with diabetes aims to mitigate cardiovascular kidney and metabolic risk.

Post-hoc phase 2 data show coramitug induces an early, transient hsCRP rise followed by a sustained 52-week inflammatory reduction in ATTR-CM.

Symptoms persist or become worse in more than a third of patients hospitalized due to heart failure, research shows.

Adding evolocumab to lipid-lowering therapy reduces all-cause mortality in high-risk patients without a history of myocardial infarction or stroke.